MTOR and prostate cancer: For instance, C Coarfa et al.'s study identified significant suppression of these miRNAs in metastatic prostate cancer, where their re‐expression curtailed cell proliferation and impacted critical oncogenic pathways, including apoptosis, metastasis, cell cycle regulation, and Akt/mTOR signaling, as well as the androgen receptor axis [31].